Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial
Our findings highlight the potential of epigenetic modulators to re-shape the tumor microenvironment of PROC toward a more inflammed phenotype and may point to approaches to augment immunotherapy response.
Authors
- Julia L. Boland (ORCID: https://orcid.org/0000-0001-5637-2696)
- Victor E. Velculescu (ORCID: https://orcid.org/0000-0003-1195-438X)
- Blair V. Landon (ORCID: https://orcid.org/0000-0002-5235-7410)
- Archana Balan (ORCID: https://orcid.org/0000-0003-1283-577X)
- Guneet Kaleka
- Valsamo Anagnostou (ORCID: https://orcid.org/0000-0001-9480-3047)
- Cynthia A. Zahnow (ORCID: https://orcid.org/0009-0007-1840-5558)
- John A. Glaspy (ORCID: https://orcid.org/0000-0002-1800-9076)
- Jaime Wehr
- Andrea E. Wahner Hendrickson
- Christopher Cherry
- Boris Winterhoff
- Stephen B. Baylin
- Deborah K. Armstrong
- Dennis J. Slamon
- Gottfried E. Konecny
- Akshaya V. Annapragada
Institutions
- University of Minnesota (US)
- Van Andel Institute (US)
- Johns Hopkins University (US)
- University of California, Los Angeles (US)
- Mayo Clinic in Arizona (US)
- Olive View-UCLA Medical Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Communications Medicine
- Published
- 2026-02-06
- DOI
- https://doi.org/10.1038/s43856-026-01404-0
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Celgene
- Honorable Tina Brozman Foundation
- Gray Foundation
- National Institutes of Health